{"id":"540b5f17-970f-5c51-89af-33c63e38cd98","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-protease-platelet-link","predicate":"requires_proteolytic_activity_for","statement":"Bromelain fractions II and III had both proteolytic and platelet-aggregation-inhibitory activity, and oxidation with sodium tetrathionate abolished both activities.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"1e70e964-924f-5ed2-9a1d-bd753a159102","mechanism_event_label":"Bromelain fractions II and III had both proteolytic and platelet-aggregation-inhibitory activity, and oxidation with sodium tetrathionate abolished both activities.","subject":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"object":{"id":"7b4963e9-6cbe-5340-b19c-5141bfd3b8b5","slug":"human-platelet-aggregation","display_name":"Human platelet aggregation, agonist specified","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"1e70e964-924f-5ed2-9a1d-bd753a159102","stable_key":"773f772e-bf8e-5e52-a2a2-6dd694d67f5d:bromelain-protease-platelet-link-event","event_type":"observed_relationship","label":"Bromelain fractions II and III had both proteolytic and platelet-aggregation-inhibitory activity, and oxidation with sodium tetrathionate abolished both activities.","description":"Bromelain fractions II and III had both proteolytic and platelet-aggregation-inhibitory activity, and oxidation with sodium tetrathionate abolished both activities.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"6a3990e6-85af-58c7-8087-8a251db842fa","slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"7b4963e9-6cbe-5340-b19c-5141bfd3b8b5","slug":"human-platelet-aggregation","display_name":"Human platelet aggregation, agonist specified","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"Purified bromelain fractions with or without oxidation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"Acute","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Fractionated commercial bromelain and platelet assays","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"The experiment links activities but did not identify the platelet substrate or establish an oral antithrombotic dose.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"bromelain","display_name":"Bromelain","entity_type_key":"peptide"}},{"dimension":"organism","value_text":"Fractionated commercial bromelain and platelet assays","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Bromelain fractions II and III had both proteolytic and platelet-aggregation-inhibitory activity, and oxidation with sodium tetrathionate abolished both activities.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"Chromatographic fractionation and characterization of the active platelet aggregation inhibitory factor from bromelain. (1979). https://pubmed.ncbi.nlm.nih.gov/485732/","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"In vitro","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Protease activity and platelet aggregation","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"09af111f-d678-5063-9a65-4ec5d1217f4c","evidence_kind":"source_excerpt","locator":"Lines 121-130","start_line":121,"end_line":130,"excerpt":"## bromelain-protease-platelet-link\nBromelain fractions II and III had both proteolytic and platelet-aggregation-inhibitory activity, and oxidation with sodium tetrathionate abolished both activities.\nModel/species: Fractionated commercial bromelain and platelet assays\nTissue/system: Protease activity and platelet aggregation\nExposure: Purified bromelain fractions with or without oxidation\nRoute: In vitro\nDuration: Acute\nLimits: The experiment links activities but did not identify the platelet substrate or establish an oral antithrombotic dose.\nPrimary reference: Chromatographic fractionation and characterization of the active platelet aggregation inhibitory factor from bromelain. (1979). https://pubmed.ncbi.nlm.nih.gov/485732/\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Fractionated commercial bromelain and platelet assays","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"9d363b4e-f438-5664-9d74-99c2e359391d","stable_key":"import-773f772e-bf8e-5e52-a2a2-6dd694d67f5d","title":"Bromelain: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"b328dbb8082bea612bb2c40d6ff41fa670f6e62f714bd014c90627fcab86e95b","revision_id":"1c10d22e-ecdf-56ef-b820-bb21182a9577","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}